Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 9, 2007

View Archived Issues

Merck & Co. reports preliminary in vivo results of novel DPP-IV inhibitor

Adenovirus-based HIV-1 vaccine safe in humans

Snapshots of new study results for epilepsy treatments

Enzon files IND for HIF-1alpha antagonist

Novel agents for treating neurological disorders disclosed in recent patents

New JAK3 inhibitors emerge from Rigel R&D

U.S. orphan drug status for INNO-406 in Gleevec-resistant or intolerant CML

Novel therapeutic agents for gastrointestinal disorders claimed in recent patents

Galapagos extends and expands drug discovery collaboration with Amgen

DOR receives payment from Sigma-Tau for rights to negotiate orBec alliance

Sequenom and Qiagen collaborate on prenatal diagnostics

OSI licenses GKA program for type 2 diabetes to Lilly

New phase IIb trial begins for microplasmin in vitrectomy

Xytis signs CRADA for neboglamine in cocaine addiction

Semafore completes Series B equity financing

Tengion studies urinary neobladder construct in phase II

ALK-Abello and Schering-Plough form immunotherapy alliance

Launch of Merck Serono

GSK completes acquisition of Domantis

TargeGen selects Jak2 inhibitor TG-101348 for clinical development

Shionogi and Nippon Kayaku end Japanese development agreement for NS-75B

ATC shows potential for combination therapy with tipranavir

HY-10275 meets endpoints in insomnia study

HGF gene plasmid shows potential to improve perfusion in patients with CLI

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...